Nintedanib as Switch Maintenance Treatment of Pleural Malignant Mesothelioma

Phase 2 Terminated 37 enrolled European Organisation for Research and Treatment of Cancer - EORTC

RandomizedParallel-groupTriple-blindTreatment

Summary

This is a multicenter, randomized, 1:1, double blinded phase II trial. Patients with unresectable malignant pleural mesothelioma (MPM) will be randomized between arm A: nintedanib and arm B:placebo

Timeline

Start: 2018-02-04
Primary completion: 2023-10-12
Completion: 2024-01-10

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Nintedanib	Small molecule	200 mg	Oral

Nintedanib as Switch Maintenance Treatment of Pleural Malignant Mesothelioma

Summary

Timeline

Drugs

Indications